Future studies incorporating the flexible features of the EPO-GEMM approach will enable the further dissection of mechanisms that dictate ovarian cancer response and resistance and, more broadly, expedite investigation of other clinically relevant aspects of this disease. This evidence concerns the gene EPO and ovarian cancer.